Clinical trial
A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
NCT06097260 is registered in ClinicalTrials.gov with Pliant Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
- Lead sponsor
- Pliant Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 16, 2023
- Completion date
- April 4, 2025
- Enrollment
- 320 (actual)
- Sites
- 268
Conditions
As the registry lists them; a condition with its own page is linked.